- Home
- REFI vs CCCC Comparison
REFI vs CCCC Comparison
Compare REFI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- CCCC
- Stock Information
- Founded
- REFI 2021
- CCCC 2015
- Country
- REFI United States
- CCCC United States
- Employees
- REFI N/A
- CCCC N/A
- Industry
- REFI Real Estate Investment Trusts
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- CCCC Health Care
- Exchange
- REFI Nasdaq
- CCCC Nasdaq
- Market Cap
- REFI 304.4M
- CCCC 104.4M
- IPO Year
- REFI 2021
- CCCC 2020
- Fundamental
- Price
- REFI $14.26
- CCCC $1.48
- Analyst Decision
- REFI Strong Buy
- CCCC Buy
- Analyst Count
- REFI 3
- CCCC 3
- Target Price
- REFI $20.00
- CCCC $12.00
- AVG Volume (30 Days)
- REFI 105.4K
- CCCC 1.4M
- Earning Date
- REFI 08-06-2025
- CCCC 07-31-2025
- Dividend Yield
- REFI 13.19%
- CCCC N/A
- EPS Growth
- REFI N/A
- CCCC N/A
- EPS
- REFI 1.88
- CCCC N/A
- Revenue
- REFI $56,790,054.00
- CCCC $39,783,000.00
- Revenue This Year
- REFI $15.53
- CCCC N/A
- Revenue Next Year
- REFI $6.70
- CCCC N/A
- P/E Ratio
- REFI $7.58
- CCCC N/A
- Revenue Growth
- REFI 4.68
- CCCC 98.56
- 52 Week Low
- REFI $12.76
- CCCC $1.09
- 52 Week High
- REFI $16.47
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- REFI 48.62
- CCCC 48.83
- Support Level
- REFI $13.85
- CCCC $1.36
- Resistance Level
- REFI $14.59
- CCCC $1.60
- Average True Range (ATR)
- REFI 0.29
- CCCC 0.12
- MACD
- REFI 0.01
- CCCC -0.00
- Stochastic Oscillator
- REFI 51.76
- CCCC 31.58
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.